Evgeny Kopyltsov

6.2k total citations · 1 hit paper
25 papers, 438 citations indexed

About

Evgeny Kopyltsov is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Evgeny Kopyltsov has authored 25 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 11 papers in Surgery. Recurrent topics in Evgeny Kopyltsov's work include Bladder and Urothelial Cancer Treatments (11 papers), Prostate Cancer Treatment and Research (9 papers) and Renal cell carcinoma treatment (7 papers). Evgeny Kopyltsov is often cited by papers focused on Bladder and Urothelial Cancer Treatments (11 papers), Prostate Cancer Treatment and Research (9 papers) and Renal cell carcinoma treatment (7 papers). Evgeny Kopyltsov collaborates with scholars based in Russia, United States and France. Evgeny Kopyltsov's co-authors include Cora N. Sternberg, Neal D. Shore, Anil Kapoor, Fred Saad, Michael Staehler, Paul Bevan, Hiroyoshi Suzuki, Maha Hussain, Stephan Störkel and Nicholas M. Donin and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Evgeny Kopyltsov

22 papers receiving 429 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

2023 99 citations Maha Hussain, Bertrand Tombal et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Evgeny Kopyltsov

Since Specialization

Citations

This map shows the geographic impact of Evgeny Kopyltsov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgeny Kopyltsov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgeny Kopyltsov more than expected).

Fields of papers citing papers by Evgeny Kopyltsov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgeny Kopyltsov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgeny Kopyltsov. The network helps show where Evgeny Kopyltsov may publish in the future.

Co-authorship network of co-authors of Evgeny Kopyltsov

This figure shows the co-authorship network connecting the top 25 collaborators of Evgeny Kopyltsov. A scholar is included among the top collaborators of Evgeny Kopyltsov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgeny Kopyltsov. Evgeny Kopyltsov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial 2025 ·European Urology Oncology ·Petros Grivas, Jeanny B. Aragon‐Ching, Joaquim Bellmunt, Yohann Loriot, Miguel Á. Climent Durán, Srikala S. Sridhar, Po‐Jung Su, Se Hoon Park, Evgeny Kopyltsov, Yoshiaki Yamamoto, (unknown), (unknown), (unknown), Juliane Manitz, Mairead Kearney, Michael Schlichting, Thomas Powles	0
2	Maintenance therapy with avelumab as the first-line treatment in patients with metastatic urothelial carcinoma: A real-world, ambispective RAVE-Bladder study. 2024 ·Journal of Clinical Oncology ·(unknown), А. В. Султанбаев, (unknown), (unknown), Anastasia Mochalova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Evgeny Kopyltsov, М. И. Волкова, Ilya Tsimafeyeu	1
3	A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer 2024 ·European Journal of Cancer ·Ulka N. Vaishampayan, (unknown), Robert Dreicer, Elisabeth I. Heath, Tomáš Büchler, Péter Árkosy, (unknown), Paweł Wiechno, Evgeny Kopyltsov, Sergey Orlov, (unknown), Maria Smagina, Sergei Varlamov, Neal D. Shore	3
4	PRIORITI: Phase 4 study of triptorelin or active surveillance in high‐risk prostate cancer 2024 ·Asia-Pacific Journal of Clinical Oncology ·Vsevolod Matveev, Xin Gao, Evgeny Kopyltsov, Jindan Luo, Qiang Wei, Dingwei Ye, Fang-Jian Zhou, (unknown), Aude Houchard, Adnan Mahmood, Liping Xie	0
5	Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study 2023 ·European Urology Oncology ·Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso‐Gordoa, Masatoshi Eto, Thomas E. Hutson, Robert J. Motzer, Eric Winquist, Pablo Maroto, Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frédéric Rolland, Mototsugu Oya, (unknown), Kenichi Saito, Jodi A. McKenzie, Camillo Porta	16
6	Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial breakdown → 2023 ·Journal of Clinical Oncology ·Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Neal D. Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Bögemann, Dingwei Ye, Felipe José Silva Melo Cruz, Hiroyoshi Suzuki, (unknown), Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R. Smith	99
7	Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study. 2023 ·Journal of Clinical Oncology ·Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Neal D. Shore, Evgeny Kopyltsov, Arash Rezazadeh, Martin Boegemann, Dingwei Ye, Felipe Melo Cruz, Hiroyoshi Suzuki, (unknown), Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R. Smith	3
8	Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma 2022 ·European Urology ·Petros Grivas, Evgeny Kopyltsov, Po‐Jung Su, (unknown), Se Hoon Park, Yoshiaki Yamamoto, Peter C.C. Fong, Christophe Tournigand, Miguel Á. Climent Durán, Aristotelis Bamias, Claudia Caserta, Jane Chang, Paul Cislo, Alessandra di Pietro, Jing Wang, Thomas Powles	32
9	A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B. 2022 ·Journal of Clinical Oncology ·Neal D. Shore, Thomas Powles, Jens Bedke, Matt D. Galsky, Evgeny Kopyltsov, Andrea Necchi, Joan Palou, Jennifer Vermette, (unknown), Kristen J. Pierce, Rossano Cesari, Gary D. Steinberg	2
10	A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC). 2022 ·Journal of Clinical Oncology ·Ulka N. Vaishampayan, (unknown), Elisabeth I. Heath, Robert Dreicer, Tomáš Büchler, Péter Árkosy, Tibor Csőszi, Paweł Wiechno, (unknown), Evgeny Kopyltsov, Neal D. Shore, (unknown), Sergey Orlov, (unknown), Maria Smagina, Sergey Varlamov, Nicholas J. Vogelzang	1
11	660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update 2021 ·Annals of Oncology ·Toni K. Choueiri, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert J. Motzer, Viktor Grünwald, Thomas E. Hutson, María José Méndez-Vidal, (unknown), Eric Winquist, (unknown), Pablo Maroto, Tomáš Büchler, Toshio Takagi, (unknown), D. Xing, A. David Smith, Thomas Powles	19
12	Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. 2021 ·Journal of Clinical Oncology ·Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso Gordoa, Masatoshi Eto, Thomas E. Hutson, Robert J. Motzer, Eric Winquist, (unknown), Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frédéric Rolland, Mototsugu Oya, (unknown), Kenichi Saito, Alan D. Smith, Camillo Porta	15
13	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). 2021 ·Journal of Clinical Oncology ·Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Evgeny Kopyltsov, M.J. Méndez Vidal, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Jaime R. Merchan, Alan D. Smith, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri	24
14	Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC). 2021 ·Journal of Clinical Oncology ·Ulka N. Vaishampayan, (unknown), Neal D. Shore, Elisabeth I. Heath, Robert Dreicer, Tomáš Büchler, Péter Árkosy, Tibor Csőszi, Paweł Wiechno, Evgeny Kopyltsov, (unknown), (unknown), Sergei Varlamov, Nicholas J. Vogelzang	0
15	745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC) 2020 ·Annals of Oncology ·Thomas Powles, Evgeny Kopyltsov, (unknown), Francis Parnis, S.H. Park, Yasuhiro Yamamoto, Peter C.C. Fong, Christophe Tournigand, Miguel Á. Climent Durán, Aristotelis Bamias, Claudia Caserta, Jane Chang, (unknown), Alessandra di Pietro, (unknown), Petros Grivas	8
16	704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 2020 ·Annals of Oncology ·Petros Grivas, S.H. Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Shilpa Gupta, Bo Huang, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Thomas Powles	10
17	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. 2020 ·Journal of Clinical Oncology ·Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Alessandra di Pietro, Petros Grivas	55
18	Surgical technique stabilization of urethrovesical anastomosis in order to improve the results of early recovery of urine retention after retropubic prostatectomy 2018 ·Cancer Urology ·(unknown), B. Yа. Alekseev, (unknown), Evgeny Kopyltsov, (unknown), (unknown)	1
19	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). 2017 ·Journal of Clinical Oncology ·Robert J. Motzer, Naomi B. Haas, Frede Donskov, Marine Gross‐Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae‐Lyun Lee, Bohuslav Melichar, Brian I. Rini, Toni K. Choueiri, Milada Zemanová, Lori Wood, Dirk Fahlenkamp, M. Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg	22
20	Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma 2016 ·JAMA Oncology ·Karim Chamie, Nicholas M. Donin, (unknown), Paul Bevan, (unknown), Olaf G. Wilhelm, Stephan Störkel, Jonathan Said, (unknown), Robert E. Hawkins, (unknown), Anil Kapoor, Evgeny Kopyltsov, Michael Staehler, Kimmo Taari, Alberto Julius Alves Wainstein, Allan J. Pantuck, Arie S. Belldegrun	99

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact